Last reviewed · How we verify
solifenacin succinate suspension
solifenacin succinate suspension is a Muscarinic M3 receptor antagonist Small molecule drug developed by Astellas Pharma Inc. It is currently FDA-approved for Overactive bladder with symptoms of urge incontinence, urgency, and frequency. Also known as: YM905, VESIcare, solifenacin succinate.
Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder.
Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.
At a glance
| Generic name | solifenacin succinate suspension |
|---|---|
| Also known as | YM905, VESIcare, solifenacin succinate |
| Sponsor | Astellas Pharma Inc |
| Drug class | Muscarinic M3 receptor antagonist |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Solifenacin selectively blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, preventing involuntary contractions. This reduces urinary frequency, urgency, and incontinence episodes associated with overactive bladder syndrome. The suspension formulation allows for flexible dosing and is particularly useful in patients who have difficulty swallowing tablets.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
Common side effects
- Dry mouth
- Constipation
- Blurred vision
- Urinary retention
- Headache
- Dizziness
Key clinical trials
- A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity (PHASE3)
- A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (PHASE3)
- A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (PHASE3)
- A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) (PHASE3)
- Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents (PHASE1)
- Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder (PHASE1)
- A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation (PHASE1)
- Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- solifenacin succinate suspension CI brief — competitive landscape report
- solifenacin succinate suspension updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI
Frequently asked questions about solifenacin succinate suspension
What is solifenacin succinate suspension?
How does solifenacin succinate suspension work?
What is solifenacin succinate suspension used for?
Who makes solifenacin succinate suspension?
Is solifenacin succinate suspension also known as anything else?
What drug class is solifenacin succinate suspension in?
What development phase is solifenacin succinate suspension in?
What are the side effects of solifenacin succinate suspension?
What does solifenacin succinate suspension target?
Related
- Drug class: All Muscarinic M3 receptor antagonist drugs
- Target: All drugs targeting M3 muscarinic acetylcholine receptor
- Manufacturer: Astellas Pharma Inc — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Overactive bladder with symptoms of urge incontinence, urgency, and frequency
- Also known as: YM905, VESIcare, solifenacin succinate
- Compare: solifenacin succinate suspension vs similar drugs
- Pricing: solifenacin succinate suspension cost, discount & access